Dental-craniofacial manifestation and treatment of rare diseases in China

doi:10.7518/hxkq.2019.02.003

Abstract

Abstract:

Rare diseases are genetic, chronic, and incurable disorders with relatively low prevalence. Thus, diagnosis and management strategies for such diseases are currently limited. This situation is exacerbated by insufficient medical sources for these diseases. The National Health and Health Committee of China recently first provided a clear definition of 121 rare diseases in the Chinese population. In this study, we summarize several dental-craniofacial manifestations associated with some rare diseases to provide a reference for dentists and oral maxillofacial surgeons aiming at fast-tracking diagnosis for the management of these rare diseases.

Key words: rare disease, stomatology, clinical feature, treatment

CLC Number:

En Luo,Bing Shi,Qianming Chen,Xuedong Zhou. Dental-craniofacial manifestation and treatment of rare diseases in China[J]. West China Journal of Stomatology, 2019, 37(2): 130-142.

Figures/Tables 4

Tab 1

Tab 2

Dental-craniofacial manifestations of bone tissue abnormality related rare diseases

罕见病	病因	主要临床表现	牙颌面表现	发生率/%*	发病时期/岁^#
OI	col1a1或 col1a2基因	骨脆性增加,长骨弯曲畸形,关	1）面部畸形伴频发骨折	60	-
	突变	节松弛,蓝灰色巩膜,听力受损	2）牙本质发育不全	28~80	0~14
			3）错畸形,牙迟萌	60~80	0.5~6
HR	磷酸调节内肽酶基因	身材矮小,骨骼畸形,骨痛,听	1）原发性颅缝早闭	-	出生时
	的功能丧失型突变	力受损	2）反复性非龋源性、非外伤性的脓肿	10.5~64.7	0~6
			3）牙迟萌,牛牙症	42.1~85.7	0~14
HPP	组织非特异性碱性磷	围产期HPP：膜状颅、肢体畸	1）颅骨骨缝未闭,颅骨骨化不完全	31~40	出生时
	酸酶基因突变	形、呼吸衰竭;婴幼儿期HPP：	2）乳牙早失,壳状牙,牙本质发育不	14	0~14
		发育受限、连枷胸;儿童期	全,恒牙龋坏
		HPP：行走障碍、反复性骨折、
		囟门未闭;成人期HPP：足部疼
		痛、股骨假性骨折、关节炎
MFS	fbn1 基因突变	四肢细长,蜘蛛指（趾）,晶状	1）颅骨长而窄,腭盖高拱,颌骨发育	63.6	0~14
		体异位;胸闷气短,四肢发凉	不良
			2）牙列拥挤,开	-	0~14
MAS	gnas基因突变	多发性骨纤维异常增殖症,咖啡	1）面部发育不对称,伴有广泛性骨纤	62~100	0~6
		色皮肤色素沉着,内分泌疾病	维异常增殖症
		（性早熟、睾丸发育异常、甲状	2）口腔黏膜色素沉着	70~90	出生时
		腺功能亢进等）	3）错畸形,牙本质发育不良,牛牙	-	0.5~14
			症,高患龋风险
KS	游离GnRH缺乏	青春期推迟,原发性闭经或睾丸	1）唇裂,腭裂,腭盖高拱	25~30	出生时
		发育异常,嗅觉完全丧失,听力	2）先天缺牙、畸形牙等	5~10	0.5~6
		受损
FA	fa或fa样基因突变	骨髓衰竭,急性髓系白血病,皮	1）小头畸形,三角形面部	51	0~6
		肤色素沉着,身材矮小,桡骨和	2）头颈部肿瘤	14	>18
		拇指异常

Tab 2

Tab 3

Tab 4

References 147

[1]	Dawkins HJS, Draghia-Akli R, Lasko P , et al. Progress in rare diseases research 2010—2016: an IRDiRC perspective[J]. Clin Transl Sci, 2018,11(1):11-20. doi: 10.1111/cts.12501 URL
[2]	Azie N, Vincent J . Rare diseases: the bane of modern society and the quest for cures[J]. Clin Pharmacol Ther, 2012,92(2):135-139. doi: 10.1038/clpt.2012.97 URL
[3]	Schieppati A, Henter JI, Daina E , et al. Why rare diseases are an important medical and social issue[J]. Lancet, 2008,371(9629):2039-2041. doi: 10.1016/S0140-6736(08)60872-7 URL
[4]	Melnikova I . Rare diseases and orphan drugs[J]. Nat Rev Drug Discov, 2012,11(4):267-268.
[5]	Ekins S . Industrializing rare disease therapy discovery and development[J]. Nat Biotechnol, 2017,35(2):117-118.
[6]	James W, Berger T, Elston D . Andrews’ diseases of the skin: clinical dermatology[M]. 12th ed. Philadelphia: Elsevier, 2016: 573-582
[7]	Halai TN, Stevens C . Ectodermal dysplasia: a clinical overview for the dental practitioner[J]. Dent Update, 2015,42(8):779-790. doi: 10.12968/denu.2015.42.8.779 URL
[8]	Lexner MO, Bardow A, Hertz JM , et al. Anomalies of tooth formation in hypohidrotic ectodermal dysplasia[J]. Int J Paediatr Dent, 2007,17(1):10-18. doi: 10.1111/ipd.2007.17.issue-1 URL
[9]	Rad AS, Siadat H, Monzavi A , et al. Full mouth rehabilitation of a hypohidrotic ectodermal dysplasia patient with dental implants: a clinical report[J]. J Prosthodont, 2007,16(3):209-213. doi: 10.1111/jopr.2007.16.issue-3 URL
[10]	Borzabadi-Farahani A . Orthodontic considerations in restorative management of hypodontia patients with endosseous implants[J]. J Oral Implantol, 2012,38(6):779-791. doi: 10.1563/AAID-JOI-D-11-00022 URL
[11]	Pober BR . Williams-Beuren syndrome[J]. N Engl J Med, 2010,362(3):239-252. doi: 10.1056/NEJMra0903074 URL
[12]	Torres CP, Valadares G, Martins MI , et al. Oral findings and dental treatment in a child with Williams-Beuren syndrome[J]. Braz Dent J, 2015,26(3):312-316. doi: 10.1590/0103-6440201300335 URL
[13]	Martens MA, Wilson SJ, Reutens DC . Research review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype[J]. J Child Psychol Psychiatry, 2008,49(6):576-608. doi: 10.1111/j.1469-7610.2008.01887.x URL
[14]	Lee WH, Tai WC, Wu PY . Congenital erythropoietic porphyria[J]. Dermatologica Sinica, 2012,30(2):62-65. doi: 10.1016/j.dsi.2011.09.012 URL
[15]	Berry AA, Desnick RJ, Astrin KH , et al. Two brothers with mild congenital erythropoietic porphyria due to a novel genotype[J]. Arch Dermatol, 2005,141(12):1575-1579.
[16]	Poh-Fitzpatrick MB . The erythropoietic porphyrias[J]. Dermatol Clin, 1986,4(2):291-296. doi: 10.1016/S0733-8635(18)30833-7 URL
[17]	Fritsch C, Bolsen K, Ruzicka T , et al. Congenital erythropoietic porphyria[J]. J Am Acad Dermatol, 1997,36(4):594-610. doi: 10.1016/S0190-9622(97)70249-4 URL
[18]	Hallai N, Anstey A, Mendelsohn S , et al. Pregnancy in a patient with congenital erythropoietic porphyria[J]. N Engl J Med, 2007,357(6):622-623. doi: 10.1056/NEJMc070009 URL
[19]	Katugampola RP, Badminton MN, Finlay AY , et al. Congenital erythropoietic porphyria: a singleobserver clinical study of 29 cases[J]. Br J Dermatol, 2012,167(4):901-913. doi: 10.1111/bjd.2012.167.issue-4 URL
[20]	Peinado CM, de Heredia CD, To-Figueras J , et al. Successful treatment of congenital erythropoietic porphyria using matched unrelated hematopoietic stem cell transplantation[J]. Pediatr Dermatol, 2013,30(4):484-489. doi: 10.1111/pde.2013.30.issue-4 URL
[21]	Katugampola RP, Anstey AV, Finlay AY , et al. A management algorithm for congenital erythropoietic porphyria derived from a study of 29 cases[J]. Br J Dermatol, 2012,167(4):888-900. doi: 10.1111/bjd.2012.167.issue-4 URL
[22]	Forlino A, Marini JC . Osteogenesis imperfecta[J]. Lancet, 2016,387(10028):1657-1671. doi: 10.1016/S0140-6736(15)00728-X URL
[23]	Rauch F, Glorieux FH . Osteogenesis imperfecta[J]. Lancet, 2004,363(9418):1377-1385. doi: 10.1016/S0140-6736(04)16051-0 URL
[24]	Brizola E, Staub AL, Félix TM . Muscle strength, joint range of motion, and gait in children and adolescents with osteogenesis imperfecta[J]. Pediatr Phys Ther, 2014,26(2):245-252. doi: 10.1097/PEP.0000000000000042 URL
[25]	Swinnen FK , Coucke PJ, de Paepe AM , et al. Osteogenesis imperfecta: the audiological phenotype lacks correlation with the genotype[J]. Orphanet J Rare Dis, 2011,6(1):88. doi: 10.1186/1750-1172-6-88 URL
[26]	Land C, Rauch F, Montpetit K , et al. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta[J]. J Pediatr, 2006,148(4):456-460. doi: 10.1016/j.jpeds.2005.10.041 URL
[27]	Carpenter TO, Imel EA, Holm IA , et al. A clinician’s guide to X-linked hypophosphatemia[J]. J Bone Miner Res, 2011,26(7):1381-1388. doi: 10.1002/jbmr.340 URL
[28]	Lee JY, Imel EA . The changing face of hypophosphatemic disorders in the FGF-23 era[J]. Pediatr Endocrinol Rev, 2013,10(Suppl 2):367-379.
[29]	Pavone V, Testa G, Gioitta Iachino S , et al. Hypophosphatemic rickets: etiology, clinical features and treatment[J]. Eur J Orthop Surg Traumatol, 2015,25(2):221-226. doi: 10.1007/s00590-014-1496-y URL
[30]	Kinoshita Y, Fukumoto S . X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment[J]. Endocr Rev, 2018,39(3):274-291. doi: 10.1210/er.2017-00220 URL
[31]	Vakharia JD, Matlock K, Taylor HO , et al. Craniosynostosis as the presenting feature of X-linked hypophosphatemic rickets[J]. Pediatrics, 2018,141(Suppl 5):S515-S519. doi: 10.1542/peds.2017-2522 URL
[32]	Opsahl Vital S, Gaucher C, Bardet C , et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization[J]. Bone, 2012,50(4):989-997. doi: 10.1016/j.bone.2012.01.010 URL
[33]	Souza AP, Kobayashi TY, Lourenço Neto N , et al. Dental manifestations of patient with vitamin D-resistant rickets[J]. J Appl Oral Sci, 2013,21(6):601-606. doi: 10.1590/1679-775720130249 URL
[34]	Rabbani A, Rahmani P, Ziaee V , et al. Dental problems in hypophosphatemic rickets, a cross sectional study[J]. Iran J Pediatr, 2012,22(4):531-534.
[35]	Sabandal MM, Robotta P, Bürklein S , et al. Review of the dental implications of X-linked hypophosphataemic rickets (XLHR)[J]. Clin Oral Investig, 2015,19(4):759-768. doi: 10.1007/s00784-015-1425-4 URL
[36]	Sharkey MS, Grunseich K, Carpenter TO . Contemporary medical and surgical management of X-linked hypophosphatemic rickets[J]. J Am Acad Orthop Surg, 2015,23(7):433-442. doi: 10.5435/JAAOS-D-14-00082 URL
[37]	Makitie O, Toiviainen-Salo S, Marttinen E , et al. Metabolic control and growth during exclusive growth hormone treatment in X-linked hypophosphatemic rickets[J]. Horm Res, 2008,69(4):212-220.
[38]	Linglart A, Biosse-Duplan M . Hypophosphatasia[J]. Curr Osteoporos Rep, 2016,14(3):95-105. doi: 10.1007/s11914-016-0309-0 URL
[39]	Millán JL . The role of phosphatases in the initiation of skeletal mineralization[J]. Calcif Tissue Int, 2013,93(4):299-306. doi: 10.1007/s00223-012-9672-8 URL
[40]	Millán JL, Plotkin H . Hypophosphatasia—pathophysiology and treatment[J]. Actual En Osteol, 2012,8(3):164-182.
[41]	Whyte MP, Zhang F, Wenkert D , et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients[J]. Bone, 2015,75:229-239. doi: 10.1016/j.bone.2015.02.022 URL
[42]	Whyte MP . Hypophosphatasia—aetiology, nosology, pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol, 2016,12(4):233-246. doi: 10.1038/nrendo.2016.14 URL
[43]	Whyte MP, Rockman-Greenberg C, Ozono K , et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia[J]. J Clin Endocrinol Metab, 2016,101(1):334-342. doi: 10.1210/jc.2015-3462 URL
[44]	Bianchi ML . Hypophosphatasia: an overview of the disease and its treatment[J]. Osteoporos Int, 2015,26(12):2743-2757. doi: 10.1007/s00198-015-3272-1 URL
[45]	Hofmann C, Girschick HJ, Mentrup B . Clinical aspects ofhypophosphatasia: an update[J]. Clinic Rev Bone Miner Metab, 2013,11(2):60-70. doi: 10.1007/s12018-013-9139-0 URL
[46]	Whyte MP . Physiological role of alkaline phosphatase explored in hypophosphatasia[J]. Ann N Y Acad Sci, 2010,1192(1):190-200. doi: 10.1111/j.1749-6632.2010.05387.x URL
[47]	Arun R, Khazim R, Webb JK , et al. Scoliosis in association with infantile hypophosphatasia: a case study in two siblings[J]. Spine, 2005,30(16):E471-E476. doi: 10.1097/01.brs.0000174277.03526.de URL
[48]	Sutton RA, Mumm S, Coburn SP , et al. “Atypical femoral fractures” during bisphosphonate exposure in adult hypophosphatasia[J]. J Bone Miner Res, 2012,27(5):987-994. doi: 10.1002/jbmr.1565 URL
[49]	Coe JD, Murphy WA, Whyte MP . Management of femoral fractures and pseudofractures in adult hypophosphatasia[J]. J Bone Joint Surg Am, 1986,68(7):981-990. doi: 10.2106/00004623-198668070-00004 URL
[50]	de Roo MGA, Abeling N, Majoie CB , et al. Infantile hypophosphatasia without bone deformities presenting with severe pyridoxine-resistant seizures[J]. Mol Genet Metab, 2014,111(3):404-407. doi: 10.1016/j.ymgme.2013.09.014 URL
[51]	Rodriguez E, Bober MB, Davey L , et al. Respiratory mechanics in an infant with perinatal lethal hypophosphatasia treated with human recombinant enzyme replacement therapy[J]. Pediatr Pulmonol, 2012,47(9):917-922. doi: 10.1002/ppul.22527 URL
[52]	Taketani T, Oyama C, Mihara A , et al. Ex vivo expanded allogeneic mesenchymal stem cells with bone marrow transplantation improved osteogenesis in infants with severe hypophosphatasia[J]. Cell Transplant, 2015,24(10):1931-1943. doi: 10.3727/096368914X685410 URL
[53]	Whyte MP, Greenberg CR, Salman NJ , et al. Enzyme-replacement therapy in life-threatening hypophosphatasia[J]. N Engl J Med, 2012,366(10):904-913. doi: 10.1056/NEJMoa1106173 URL
[54]	McKusick VA . The defect in Marfan syndrome[J]. Nature, 1991,352(6333):279-281. doi: 10.1038/352279a0
[55]	Matt P, Habashi J, Carrel T , et al. Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan[J]. J Thorac Cardiovasc Surg, 2008,135(2):389-394. doi: 10.1016/j.jtcvs.2007.08.047 URL
[56]	Pyeritz RE . The Marfan syndrome[J]. Annu Rev Med, 2000,51(1):481-510. doi: 10.1146/annurev.med.51.1.481 URL
[57]	Loeys BL, Dietz HC, Braverman AC , et al. The revised Ghent nosology for the Marfan syndrome[J]. J Med Genet, 2010,47(7):476-485. doi: 10.1136/jmg.2009.072785 URL
[58]	Nollen GJ, van Schijndel KE, Timmermans J , et al. Pulmonary artery root dilatation in Marfan syndrome: quantitative assessment of an unknown criterion[J]. Heart, 2002,87(5):470-471. doi: 10.1136/heart.87.5.470 URL
[59]	Waldmuller S, Muller M, Warnecke H , et al. Genetic testing in patients with aortic aneurysms/dissections: a novel genotype/phenotype correlation[J]. Eur J Cardiothorac Surg, 2007,31(6):970-975. doi: 10.1016/j.ejcts.2007.02.027 URL
[60]	Zadeh N, Bernstein JA, Niemi AK , et al. Ectopia lentis as the presenting and primary feature in Marfan syndrome[J]. Am J Med Genet A, 2011,155A(11):2661-2668.
[61]	Nemet AY, Assia EI, Apple DJ , et al. Current concepts of ocular manifestations in Marfan syndrome[J]. Surv Ophthalmol, 2006,51(6):561-575. doi: 10.1016/j.survophthal.2006.08.008 URL
[62]	Judge DP, Dietz HC . Marfan’s syndrome[J]. Lancet, 2005,366(9501):1965-1976. doi: 10.1016/S0140-6736(05)67789-6 URL
[63]	Engelfriet PM, Boersma E, Tijssen JG , et al. Beyond the root: dilatation of the distal aorta in Marfan’s syndrome[J]. Heart, 2006,92(9):1238-1243. doi: 10.1136/hrt.2005.081638 URL
[64]	Ladouceur M, Fermanian C, Lupoglazoff JM , et al. Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome[J]. Am J Cardiol, 2007,99(3):406-409. doi: 10.1016/j.amjcard.2006.08.048 URL
[65]	Detaint D, Aegerter P, Tubach F , et al. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin Ⅱ receptor blocker therapy versus placebo in individuals with Marfan syndrome[J]. Arch Cardiovasc Dis, 2010,103(5):317-325. doi: 10.1016/j.acvd.2010.04.008 URL
[66]	Cañadas V, Vilacosta I, Bruna I , et al. Marfan syndrome. Part 2: treatment and management of patients[J]. Nat Rev Cardiol, 2010,7(5):266-276.
[67]	Dumitrescu CE, Collins MT . McCune-Albright syndrome[J]. Orphanet J Rare Dis, 2008,3:12. doi: 10.1186/1750-1172-3-12
[68]	Boyce AM, Collins MT. Fibrous dysplasia/McCune-Albright syndrome[M]. Seattle (WA): University of Washington Press, 2015: 178-186.
[69]	Brillante B, Guthrie L, Van Ryzin C . McCune-Albright syndrome: an overview of clinical features[J]. J Pediatr Nurs, 2015,30(5):815-817. doi: 10.1016/j.pedn.2015.06.009 URL
[70]	Pichard DC, Boyce AM, Collins MT , et al. Oral pigmentation in McCune-Albright syndrome[J]. JAMA Dermatol, 2014,150(7):760-763. doi: 10.1001/jamadermatol.2014.184 URL
[71]	Collins MT, Singer FR, Eugster E . McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia[J]. Orphanet J Rare Dis, 2012,7(Suppl 1):S4. doi: 10.1186/1750-1172-7-S1-S4 URL
[72]	Lee JS , FitzGibbon EJ, Chen YR , et al. Clinical guidelines for the management of craniofacial fibrous dysplasia[J]. Orphanet J Rare Dis, 2012,7(Suppl 1):S2. doi: 10.1186/1750-1172-7-S1-S2 URL
[73]	Salenave S, Boyce AM, Collins MT , et al. Acromegaly and McCune-Albright syndrome[J]. J Clin Endocrinol Metab, 2014,99(6):1955-1969. doi: 10.1210/jc.2013-3826 URL
[74]	Akintoye SO, Lee JS, Feimster T , et al. Dental characteristics of fibrous dysplasia and McCune-Albright syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2003,96(3):275-282. doi: 10.1016/S1079-2104(03)00225-7 URL
[75]	Akintoye SO, Boyce AM, Collins MT . Dental perspectives in fibrous dysplasia and McCune-Albright syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,116(3):e149-e155. doi: 10.1016/j.oooo.2013.05.023 URL
[76]	Paul SM, Gabor LR, Rudzinski S , et al. Disease severity and functional factors associated with walking performance in polyostotic fibrous dysplasia[J]. Bone, 2014,60:41-47. doi: 10.1016/j.bone.2013.11.022 URL
[77]	Stanton RP, Ippolito E, Springfield D , et al. The surgical management of fibrous dysplasia of bone[J]. Orphanet J Rare Dis, 2012,7(Suppl 1):S1. doi: 10.1186/1750-1172-7-S1-S1 URL
[78]	Tessaris D, Corrias A, Matarazzo P , et al. Thyroid abnormalities in children and adolescents with McCune-Albright syndrome[J]. Horm Res Paediatr, 2012,78(3):151-157.
[79]	Ozawa T, Tateishi C, Shirakawa M , et al. Long-term follow-up of a case of cheek hyperpigmentation associated with McCune-Albright syndrome treated with Q-switched ruby laser[J]. Dermatol Surg, 2011,37(2):263-266. doi: 10.1111/j.1524-4725.2010.01864.x URL
[80]	Stamou MI, Georgopoulos NA . Kallmann syndrome: phenotype and genotype of hypogonadotropic hypogonadism[J]. Metab Clin Exp, 2018,86:124-134. doi: 10.1016/j.metabol.2017.10.012 URL
[81]	Balasubramanian R, Crowley WF Jr. Isolated gonadotropin-releasing hormone (GnRH) deficiency[M]. Seattle: Univ. Washington Press, 2017: 1993-2019.
[82]	Balasubramanian R, Crowley WF Jr . Isolated GnRH deficiency: a disease model serving as a unique prism into the systems biology of the GnRH neuronal network[J]. Mol Cell Endocrinol, 2011,346(1/2):4-12. doi: 10.1016/j.mce.2011.07.012 URL
[83]	Boehm U, Bouloux PM, Dattani MT , et al. Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism: pathogenesis, diagnosis and treatment[J]. Nat Rev Endocrinol, 2015,11(9):547-564. doi: 10.1038/nrendo.2015.112 URL
[84]	Dodé C, Hardelin JP . Kallmann syndrome[J]. Eur J Hum Genet, 2009,17(2):139-146. doi: 10.1038/ejhg.2008.206
[85]	Laitinen EM, Hero M, Vaaralahti K , et al. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism[J]. Int J Androl, 2012,35(4):534-540. doi: 10.1111/ija.2012.35.issue-4 URL
[86]	Chan E, Wayne C, Nasr A , et al. Ideal timing of orchiopexy: a systematic review[J]. Pediatr Surg Int, 2014,30(1):87-97. doi: 10.1007/s00383-013-3429-y URL
[87]	Bagby GC, Alter BP . Fanconi anemia[J]. Semin Hematol, 2006,43(3):147-156. doi: 10.1053/j.seminhematol.2006.04.005 URL
[88]	Bagby GCJ . Genetic basis of Fanconi anemia[J]. Curr Opin Hematol, 2003,10(1):68-76. doi: 10.1097/00062752-200301000-00011 URL
[89]	Godthelp BC, Artwert F, Joenje H , et al. Impaired DNA damage-induced nuclear Rad51 foci formation uniquely characterizes Fanconi anemia group D1[J]. Oncogene, 2002,21(32):5002-5005.
[90]	Chirnomas SD, Kupfer GM . The inherited bone marrow failure syndromes[J]. Pediatr Clin North Am, 2013,60(6):1291-1310. doi: 10.1016/j.pcl.2013.09.007 URL
[91]	Rosenberg PS, Huang Y, Alter BP . Individualized risks of first adverse events in patients with Fanconi anemia[J]. Blood, 2004,104(2):350-355. doi: 10.1182/blood-2004-01-0083 URL
[92]	Sii-Felice K, Barroca V, Etienne O , et al. Role of Fanconi DNA repair pathway in neural stem cell homeostasis[J]. Cell Cycle, 2008,7(13):1911-1915. doi: 10.4161/cc.7.13.6235 URL
[93]	Törnquist AL, Martin L, Winiarski J , et al. Ocular manifestations and visual functions in patients with Fanconi anaemia[J]. Acta Ophthalmol, 2014,92(2):171-178. doi: 10.1111/aos.12132 URL
[94]	Peffault de Latour R, Peters C, Gibson B , et al. Recommendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes[J]. Bone Marrow Transplant, 2015,50(9):1168-1172.
[95]	Rio P, Banos R, Lombardo A , et al. Targeted gene therapy and cell reprogramming in Fanconi anemia[J]. EMBO Mol Med, 2014,6(6):835-848. doi: 10.15252/emmm.201303374 URL
[96]	Dulac O, Lassonde M, Sarnat HB . Pediatric neurology[J]. Handb Clin Neurol, 2013,111:287-290. doi: 10.1016/B978-0-444-52891-9.00032-4 URL
[97]	Has C, Fischer J . Inherited epidermolysis bullosa: new diagnostics and new clinical phenotypes[J]. Exp Dermatol, 2018. DOI: 10.1111/exd.13668.
[98]	Wright JT, Fine JD, Johnson L . Hereditary epidermolysis bullosa: oral manifestations and dental management[J]. Pediatr Dent, 1993,15(4):242-248.
[99]	Wright JT, Capps J, Fine JD , et al. Dental caries variation in the different epidermolysis bullosa diseases[J]. J Dent Res, 1989,68:416.
[100]	Gedde-Dahl T Jr . Epidermolysis bullosa: a clinical, genetic, and epidemiologic study[M]. Baltimore: John Hopkins Press, 1971: 303-307.
[101]	Kerns ML , DePianto D, Dinkova-Kostova AT , et al. Reprogramming of keratin biosynjournal by sulforaphane restores skin integrity in epidermolysis bullosa simplex[J]. Proc Natl Acad Sci U S A, 2007,104(36):14460-14465. doi: 10.1073/pnas.0706486104 URL
[102]	Karuman P, Gozani O, Odze RD , et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death[J]. Mol Cell, 2001,7(6):1307-1319. doi: 10.1016/S1097-2765(01)00258-1 URL
[103]	James WD, Elston DM, Berger TG . Andrews’ diseases of the skin: clinical dermatology[M]. 7th ed. Philadelphia: Elsevier, 2005: 334-337.
[104]	Choudhury S, Das A, Misra P , et al. Peutz-jeghers syndrome: a circumventable emergency[J]. Indian J Dermatol, 2018,63(2):168-171.
[105]	Boardman LA, Thibodeau SN, Schaid DJ , et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome[J]. Ann Intern Med, 1998,128(11):896-899. doi: 10.7326/0003-4819-128-11-199806010-00004 URL
[106]	Ryan DP, Hong TS, Bardeesy N . Pancreatic adenocarcinoma[J]. N Engl J Med, 2014,371(11):1039-1049. doi: 10.1056/NEJMra1404198 URL
[107]	Beggs AD, Latchford AR, Vasen HF , et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management[J]. Gut, 2010,59(7):975-986. doi: 10.1136/gut.2009.198499 URL
[108]	Higham P, Alawi F, Stoopler ET . Medical management update: peutz jeghers syndrome[J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2010,109(1):5-11. doi: 10.1016/j.tripleo.2009.08.022 URL
[109]	Tebani A, Zanoutene-Cheriet L, Adjtoutah Z , et al. Clinical and molecular characterization of patients with mucopolysaccharidosis typeⅠin an algerian series[J]. Int J Mol Sci, 2016,17(5):E743. doi: 10.3390/ijms17050743 URL
[110]	Melbouci M, Mason RW, Suzuki Y , et al. Growth impairment in mucopolysaccharidoses[J]. Mol Genet Metab, 2018,124(1):1-10. doi: 10.1016/j.ymgme.2018.03.004 URL
[111]	Neufeld EF, Muenzer J . The metabolic and molecular bases of inherited disease[M]. New York: McGraw-Hill, 2001: 3421-3452.
[112]	Różdżyńska-Świątkowska A, Jurecka A, Cieślik J , et al. Growth patterns in children with mucopolysaccharidosisⅠand Ⅱ[J]. World J Pediatr, 2015,11(3):226-231. doi: 10.1007/s12519-014-0517-6 URL
[113]	Shapiro EG, Jones SA, Escolar ML . Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations-neurological signs and symptoms[J]. Mol Genet Metab, 2017,122S:1-7.
[114]	Sarmento DJS, de Araujo TK, Mesquita G , et al. Relationship between occlusal features and enzyme replacement therapy in patients with mucopolysaccharidoses[J]. J Oral Maxillofac Surg, 2018,76(4):785-792. doi: 10.1016/j.joms.2017.10.003 URL
[115]	Kantaputra PN, Kayserili H, Guven Y , et al. Oral manifestations of 17 patients affected with mucopolysaccharidosis type Ⅵ[J]. J Inherit Metab Dis, 2014,37(2):263-268. doi: 10.1007/s10545-013-9645-8 URL
[116]	Giugliani R, Federhen A, Rojas MV , et al. MucopolysaccharidosisⅠ, Ⅱ, and Ⅵ: brief review and guidelines for treatment[J]. Genet Mol Biol, 2010,33(4):589-604. doi: 10.1590/S1415-47572010005000093 URL
[117]	Harmatz P . Enzyme replacement therapy with galsulfase for mucopolysaccharidosis Ⅵ: clinical facts and figures[J]. Turk J Pediatr, 2010,52(5):443-449.
[118]	Kubaski F, Yabe H, Suzuki Y , et al. Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis Ⅱ[J]. Biol Blood Marrow Transplant, 2017,23(10):1795-1803. doi: 10.1016/j.bbmt.2017.06.020 URL
[119]	Sawamoto K, Chen HH, Alméciga-Díaz CJ , et al. Gene therapy for mucopolysaccharidoses[J]. Mol Genet Metab, 2018,123(2):59-68. doi: 10.1016/j.ymgme.2017.12.434 URL
[120]	Mikulicz J . Uber eine eigenartige symmetrische erkrankung der tranen und mundspeicheldrusen[M]. Stuttgart: Theodor Billroth, 1892:610-630.
[121]	Yao Q, Wu G, Hoschar A . IgG4-related Mikulicz’s disease is a multiorgan lymphoproliferative disease distinct from Sjögren’s syndrome: a Caucasian patient and literature review[J]. Clin Exp Rheumatol, 2013,31(2):289-294.
[122]	Maehara T, Moriyama M, Nakashima H , et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease[J]. Ann Rheum Dis, 2012,71(12):2011-2019. doi: 10.1136/annrheumdis-2012-201477 URL
[123]	Bhatti RM, Stelow EB . IgG4-related disease of the head and neck[J]. Adv Anat Pathol, 2013,20(1):10-16. doi: 10.1097/PAP.0b013e31827b619e URL
[124]	Nelson WR, Kay S, Salley JJ . Mikulicz’s disease of the palate[J]. Ann Surg, 1963,157:152-156. doi: 10.1097/00000658-196301000-00017 URL
[125]	Abe A, Takano K, Seki N , et al. The clinical characteristics of patients with IgG4-related disease with infiltration of the labial salivary gland by IgG4-positive cells[J]. Mod Rheumatol, 2014,24(6):949-952. doi: 10.3109/14397595.2014.891964 URL
[126]	Moriyama M, Tanaka A, Maehara T , et al. Clinical characteristics of Mikulicz’s disease as an IgG4-related disease[J]. Clin Oral Investig, 2013,17(9):1995-2002. doi: 10.1007/s00784-012-0905-z URL
[127]	Merlini G, Bellotti V . Molecular mechanisms of amyloidosis[J]. N Engl J Med, 2003,349(6):583-596. doi: 10.1056/NEJMra023144 URL
[128]	Merlini G, Comenzo RL, Seldin DC , et al. Immunoglobulin light chain amyloidosis[J]. Expert Rev Hematol, 2014,7(1):143-156. doi: 10.1586/17474086.2014.858594 URL
[129]	Milani P, Merlini G, Palladini G . Light chain amyloidosis[J]. Mediterr J Hematol Infect Dis, 2018,10(1):e2018022. doi: 10.4084/mjhid.2018.022 URL
[130]	Prokaeva T, Spencer B, Kaut M , et al. Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival[J]. Arthritis Rheum, 2007,56(11):3858-3868. doi: 10.1002/(ISSN)1529-0131 URL
[131]	Merlini G, Wechalekar AD, Palladini G . Systemic light chain amyloidosis: an update for treating physicians[J]. Blood, 2013,121(26):5124-5130. doi: 10.1182/blood-2013-01-453001 URL
[132]	Mabb AM, Judson MC, Zylka MJ , et al. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes[J]. Trends Neurosci, 2011,34(6):293-303. doi: 10.1016/j.tins.2011.04.001 URL
[133]	Bird LM . Angelman syndrome: review of clinical and molecular aspects[J]. Appl Clin Genet, 2014,7:93-104.
[134]	Pelc K, Boyd SG, Cheron G , et al. Epilepsy in Angelman syndrome[J]. Seizure, 2008,17(3):211-217. doi: 10.1016/j.seizure.2007.08.004 URL
[135]	Williams CA, Driscoll DJ, Dagli AI . Clinical and genetic aspects of Angelman syndrome[J]. Genet Med, 2010,12(7):385-395. doi: 10.1097/GIM.0b013e3181def138 URL
[136]	Jaffe R, Weiss LM, Facchetti F. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. 4th ed. Lyon: IARC Press, 2008: 30-32.
[137]	Margo CE, Goldman DR . Langerhans cell histiocytosis[J]. Surv Ophthalmol, 2008,53(4):332-358. doi: 10.1016/j.survophthal.2008.04.007 URL
[138]	Chu T . Langerhans cell histiocytosis[J]. Australas J Dermatol, 2001,42(4):237-242. doi: 10.1046/j.1440-0960.2001.00527.x URL
[139]	Lian CH, Lu Y, Shen SY . Langerhans cell histiocytosis in adults: a case report and review of the literature[J]. Oncotarget, 2016,7(14):18678-18683.
[140]	Meyer JS, De Camargo B . The role of radiology in the diagnosis and follow-up of Langerhans cell histiocytosis[J]. Hematol Oncol Clin North Am, 1998,12(2):307-326. doi: 10.1016/S0889-8588(05)70512-8 URL
[141]	Ginat DT, Johnson DN, Cipriani NA . Langerhans cell histiocytosis of the temporal bone[J]. Head Neck Pathol, 2016,10(2):209-212. doi: 10.1007/s12105-015-0629-x URL
[142]	Zajko J . Mandibular Langerhans cell histiocytosis in an adult[J]. Bratisl Lek Listy, 2013,114(8):488-490.
[143]	Coppes-Zantinga A, Egeler RM . The Langerhans cell histiocytosis X files revealed[J]. Br J Haematol, 2002,116(1):3-9. doi: 10.1046/j.1365-2141.2002.03232.x URL
[144]	Krooks J, Minkov M, Weatherall AG . Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up[J]. J Am Acad Dermatol, 2018,78(6):1047-1056. doi: 10.1016/j.jaad.2017.05.060 URL
[145]	Gadner H, Minkov M, Grois N , et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis[J]. Blood, 2013,121(25):5006-5014. doi: 10.1182/blood-2012-09-455774 URL
[146]	Simko SJ , McClain KL, Allen CE . Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone[J]. Br J Haematol, 2015,169(2):299-301. doi: 10.1111/bjh.2015.169.issue-2 URL
[147]	Haroche J, Cohen-Aubart F, Emile JF , et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation[J]. Blood, 2013,121(9):1495-1500. doi: 10.1182/blood-2012-07-446286 URL

罕见病	病因	主要临床表现	牙颌面表现	发生率/%*	发病时期/岁^#
ED	外胚层结构异常	毛发异常脆弱卷曲,厚而脆弱变	1）先天缺牙,钉型牙及点状牙,牛牙	80	0.5~14
		色的指（趾）甲,皮肤红褐色色	症和釉质、牙本质发育不良
		素沉着,体温偏高,易受感染	2）唾液分泌减少	30.2	0~14
WS	第7号染色体q11.23	智力低下,心血管疾病,发育受	1）下颌较小,嘴宽大,下唇大而松弛	75~91	0~14
	区基因缺失	限,过激社会人格	2）牙排列稀疏,先天缺牙和釉质发育	38~93	0.5~6
			不良,常伴错畸形
CEP	第10号染色体q25.2-	皮肤增厚、色素沉着伴大疱性病	1）面部结痂或瘢痕	47	0~6
	q26.3区域基因突变	损,贫血,干眼症	2）牙齿：微红色荧光,边界清晰的红	73	0.5~14
			棕色变色
			3）颅骨、颌骨的圆形硬化性溶骨性病	41	>18
			损

罕见病	病因	主要临床表现	牙颌面表现	发生率/%*	发病时期/岁^#
EB	基因突变引起皮肤	手足受摩擦处易起水疱	1）口腔黏膜大疱病损,可伴瘢痕形	38.6~94.8	围产期
	表皮层和真皮层之		成或口腔前庭闭塞
	间附着的缺陷		2）釉质发育不全和/或龋病	18.1~100	0~6
PJS	lkb1基因突变	肠道良性错构瘤性息肉;手足部	唇部、口腔（牙龈、硬腭及颊）黏	90~95	0~4
		皮肤色素沉着斑点	膜的色素沉着斑块
MPS	溶酶体酶缺失或功	发育迟缓,智力低下,身材矮	1）腭盖高拱、牙槽突肥大	56.3~85.7	0~14
	能障碍	小,运动功能障碍,听力受损,	2）舌体增大、牙龈增生、前牙开	70~86.7	0~14
		呼吸窘迫,阻塞性睡眠呼吸暂	3）牙迟萌,牙列拥挤	75~85.7	0.5~6
		停,心脏瓣膜病
MD	IgG4异常沉积相关	泪腺持续性无痛性肿胀,肺间质	无痛性的腮腺、下颌下腺、舌下腺持	54.5~100	>18
	性炎症	纤维化	续性肿胀
AL	免疫球蛋白轻链异	肾衰,心衰,肝肿大	巨舌症,下颌下腺肿胀	8~20	>18
	常沉积

罕见病	病因	主要临床表现	牙颌面表现	发生率/%*	发病时期/岁^#
AS	第15号染色体q11-	发育迟缓,运动和平衡障碍,行	1）行为异常,频繁大笑,口腔运动功	75	0~6
	q13区域基因突变	为异常（过于兴奋好动等）,癫	能低下
		痫、脑电图异常	2）舌外伸,下颌前突,嘴宽大,牙齿	-	0~14
			排列稀疏
LCH	朗格汉斯细胞异常	溶骨性病损,发热,尿崩症（韩-	1）口腔黏膜溃疡、结痂或肉芽肿,并	24	0~14
	过度增殖	薛-柯病）,头皮、耳道和腹部等	伴有疼痛肿胀
		处的瘢痕性皮肤损害（勒-雪病）	2）颅颌面部骨损害呈穿凿样外观	55~80	-
			3）牙龈坏死、牙移位和牙槽骨破坏	-	-